de Silva V A, Muneeswaran K, Ratnatunga S S, Ranwala I, Gamage S, Hanwella R, Wijeyaratne C N, Chandrasekharan N V
Department of Psychiatry, Faculty of Medicine,University of Colombo, Sri Lanka.
Ceylon Med J. 2019 Jun 30;64(2):40-45. doi: 10.4038/cmj.v64i2.8889.
About 30% of patients treated with second generation antipsychotics (SGA) experience weight gain. Although there is evidence that the FTO gene is associated with obesity its role in antipsychotic induced weight gain is not so clear.
A genetic association study was carried out to identify the association between FTO rs9939609 and antipsychotic induced weight gain. Sample consisted of 180 cases and 120 controls. Cases were patients diagnosed with schizophrenia or schizoaffective disorder, treated with second-generation antipsychotics for a minimum of 3 months, and had gained at least 10% of body weight. Controls were patients with schizophrenia treated with second-generation antipsychotics for a minimum of 3 months but had not gained ≥10% of body weight. Genomic DNA was extracted from whole blood. Polymerase chain reaction of the samples was done. Real-time quantitative PCR (qPCR) was carried out using BIO-RAD CFX96 Touch TM PCR detection system.
Females were significantly more among cases (58.3%) than controls (35%). Cases (52.4%) were significantly more likely to be overweight or obese than controls (13.8%). Genotype distribution was in Hardy-Weinberg equilibrium (p=0.43). Cochran-Armitage trend test was not significant. Risk of antipsychotic induced weight gain in the AA genotype [OR 1.69 (95% CI 0.74-3.86)] and AT genotype [OR 1.1 (95% CI 0.67-1.79)] were not significantly higher than the TT genotype. Recessive model showed that AA/AT genotypes were at significantly higher risk of being obese/overweight [OR 1.84 (95% CI 1.05-3.2)].
There was no significant association between FTO rs9939609 and antipsychotic induced weight gain. AA/AT genotypes had significantly higher risk of overweight/obesity.
接受第二代抗精神病药物（SGA）治疗的患者中约30%会出现体重增加。尽管有证据表明FTO基因与肥胖有关，但其在抗精神病药物所致体重增加中的作用尚不清楚。
开展一项基因关联研究，以确定FTO rs9939609与抗精神病药物所致体重增加之间的关联。样本包括180例病例和120例对照。病例为被诊断为精神分裂症或分裂情感性障碍的患者，接受第二代抗精神病药物治疗至少3个月，且体重增加至少10%。对照为接受第二代抗精神病药物治疗至少3个月但体重增加未≥10%的精神分裂症患者。从全血中提取基因组DNA。对样本进行聚合酶链反应。使用BIO-RAD CFX96 Touch TM PCR检测系统进行实时定量PCR（qPCR）。
病例中女性比例（58.3%）显著高于对照（35%）。病例（52.4%）超重或肥胖的可能性显著高于对照（13.8%）。基因型分布符合哈迪-温伯格平衡（p=0.43）。 Cochr an-Armitage趋势检验无显著性。AA基因型[比值比（OR）1.69（95%置信区间0.74-3.86）]和AT基因型[OR 1.1（95%置信区间0.67-1.79）]的抗精神病药物所致体重增加风险并不显著高于TT基因型。隐性模型显示，AA/AT基因型肥胖/超重风险显著更高[OR 1.84（95%置信区间1.05-3.2）]。
FTO rs9939609与抗精神病药物所致体重增加之间无显著关联。AA/AT基因型超重/肥胖风险显著更高。
Zotero 插件